Information Provided By: 
Fly News Breaks for December 16, 2019
RLMD
Dec 16, 2019 | 06:41 EDT
Guggenheim analyst Yatin Suneja initiated coverage of Relmada Therapeutics with a Buy rating and $64 price target.
News For RLMD From the Last 2 Days
RLMD
Apr 18, 2024 | 11:35 EDT
In this edition of "Rising High," The Fly conducted an exclusive interview with Brendan Mitchel-Chesebro, industry analyst at BDSA, a Colorado-based cannabis market research and data analytics firm. Here are some... To see the rest of the story go to thefly.com. See Story Here
